وصف
Product Properties
|
Alternative Names |
VEGFC, VEGFc, Flt4-L, VRP, VEGF-C |
|
Species |
Human |
|
Expression Sequence |
Thr103-Arg227 |
|
Accession |
Q6FH59 |
|
Tag |
C-His-Avi |
|
Expression System |
HEK293 |
|
Molecular Weight |
The protein has a predicted MW of 17.1 kDa. Due to glycosylation, the protein migrates to 23-30 kDa based on SDS-PAGE result. |
|
Purity |
> 95% as determined by SDS-PAGE. |
|
Endotoxin |
< 1.0 EU per μg by the LAL method. |
|
Formulation |
Lyophilized from 0.22μm filtered solution in 50mM MES, 150mM NaCl (pH 6.0). Normally 8% trehalose is added as protectant before lyophilization. |
|
Appearance |
Lyophilized Powder |
|
Biological Activity |
ELISA Data: Immobilized Human VEGF-C, His Tag at 1μg/ml (100μl/well) on the plate. Dose response curve for Human VEGF R3, hFc Tag with the EC50 of 17.9ng/ml determined by ELISA . |
|
Reconstitution Method |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in 50mM MES, 150mM NaCI (pH 6.0). |
Features
High purity, high activity, low endotoxin, high batch-to-batch consistency
Storage
Store at -25 ~ -15℃, valid for 1 year after receipt. After reconstitution, store at -85 ~ -65℃, valid for 3 months.
Payment & Security
تتم معالجة معلومات الدفع الخاصة بك بشكل آمن. لا نقوم بتخزين تفاصيل بطاقة الائتمان ولا يمكننا الوصول إلى معلومات بطاقة الائتمان الخاصة بك.
You may also like
Inquiry
FAQ
The product is for research purposes only and is not intended for therapeutic or diagnostic use in humans or animals. Products and content are protected by patents, trademarks, and copyrights owned by Yeasen Biotechnology. Trademark symbols indicate the country of origin, not necessarily registration in all regions.
Certain applications may require additional third-party intellectual property rights.
Yeasen is dedicated to ethical science, believing our research should address critical questions while ensuring safety and ethical standards.